AU2002347360A1 - Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours - Google Patents

Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours

Info

Publication number
AU2002347360A1
AU2002347360A1 AU2002347360A AU2002347360A AU2002347360A1 AU 2002347360 A1 AU2002347360 A1 AU 2002347360A1 AU 2002347360 A AU2002347360 A AU 2002347360A AU 2002347360 A AU2002347360 A AU 2002347360A AU 2002347360 A1 AU2002347360 A1 AU 2002347360A1
Authority
AU
Australia
Prior art keywords
treatment
pharmaceutical compositions
solid tumours
benzofuranyl substituted
cyanoquinoline derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002347360A
Inventor
Laurent Francois Andre Hennequin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2002347360A1 publication Critical patent/AU2002347360A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AU2002347360A 2001-12-05 2002-12-05 Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours Abandoned AU2002347360A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01403127 2001-12-05
EP01403127.2 2001-12-05
PCT/GB2002/005536 WO2003047585A1 (en) 2001-12-05 2002-12-05 Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours

Publications (1)

Publication Number Publication Date
AU2002347360A1 true AU2002347360A1 (en) 2003-06-17

Family

ID=8183002

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002347360A Abandoned AU2002347360A1 (en) 2001-12-05 2002-12-05 Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours

Country Status (2)

Country Link
AU (1) AU2002347360A1 (en)
WO (1) WO2003047585A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
US11078540B2 (en) 2010-03-09 2021-08-03 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
US20080108557A1 (en) * 2004-09-29 2008-05-08 Novo Nordisk Healthcare A/G Modified Proteins
JP2010535845A (en) 2007-08-15 2010-11-25 グラクソ グループ リミテッド Substituted quinoline derivatives as H1 receptor antagonists
KR20180086187A (en) 2015-10-05 2018-07-30 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 Clearance of protein aggregates including phospholipase D and tau, and treatment of protein diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1165532C (en) * 1998-09-29 2004-09-08 惠氏控股有限公司 Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
US9084781B2 (en) 2008-12-10 2015-07-21 Novartis Ag MEK mutations conferring resistance to MEK inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
US8637246B2 (en) 2010-02-25 2014-01-28 Dana-Farber Cancer Institute, Inc. BRAF mutations conferring resistance to BRAF inhibitors
US9279144B2 (en) 2010-02-25 2016-03-08 Dana-Farber Cancer Institute, Inc. Screening method for BRAF inhibitors
EP3028699A1 (en) 2010-02-25 2016-06-08 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
US11078540B2 (en) 2010-03-09 2021-08-03 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy

Also Published As

Publication number Publication date
WO2003047585A1 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
HUP0301046A3 (en) Quinazoline derivatives for the treatment of tumours, process for their preparation and pharmaceutical compositions containing them
HUP0401514A3 (en) Pharmaceutical compositions for the treatment of asthma
AU2002324914A1 (en) Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
IL219397A0 (en) Compounds for the treatment of metabolic disorders, methods of preparing same, and pharmaceutical compositions containing same
IL157734A0 (en) Pharmaceutical compositions for the treatment of urogenital disorders
HUP0501089A2 (en) Therapeutic isoquinoline compounds and pharmaceutical compositions coutaining them
HUP0401718A3 (en) Bicyclic oxopyridine and oxopyrimidine derivatives, their use and pharmaceutical compositions containing them
IL161693A0 (en) N-adamantylmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation
HUP0400467A3 (en) 2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use
HUP0400200A3 (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
IL161582A0 (en) Use of oxindole hydrazide derivatives for the preparation of pharmaceutical compositions, certain such new derivatives and their preparation
HUP0400041A2 (en) Use of epothilone derivatives for preparation of pharmaceutical composition for the treatment of refractory tumors
IL164896A (en) Pharmaceutical compositions comprising immunoconjugates for the treatment of tumors
IL157908A0 (en) Phthalazinone derivatives and pharmaceutical compositions containing the same
HUP0401747A3 (en) Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds
IL158671A0 (en) Benzyloxy derivatives and pharmaceutical compositions containing the same
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
HUP0500024A3 (en) 6-aminomorphinane derivatives, their use and pharmaceutical compositions containing them
AU2002365665A1 (en) Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours
AU2002347360A1 (en) Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
HK1068277A1 (en) Pharmaceutical compositions comprising chelidonineor derivatives thereof
AU2003270202A8 (en) Pharmaceutical compositions useful for the treatment of cancers

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase